Abstract：
OBJECTIVE: We aimed to describe our outcomes of robotic resection for perihilar cholangiocarcinoma, the largest single institutional series in the Western hemisphere to date.
METHODS: Between 2016 and 2022, we prospectively followed all patients who underwent robotic resection for perihilar cholangiocarcinoma.
RESULTS: In total, 23 patients underwent robotic resection for perihilar cholangiocarcinoma, 18 receiving concomitant hepatectomy. The median age was 73 years. Operative time was 470 min with an estimated blood loss of 150 mL. No intraoperative conversions to open or other intraoperative complications occurred. Median length of stay was 5 days. Four postoperative complications occurred. Three readmissions occurred within 30 days with one 90-day mortality. R0 resection was achieved in 87% of patients and R1 in 13% of patients. At a median follow-up of 27 months, 15 patients were alive without evidence of disease, two patients with local recurrence at 1 year, and six were deceased.
CONCLUSIONS: Utilization of the robotic platform for perihilar cholangiocarcinoma is safe and feasible with excellent perioperative outcomes. Further studies are needed to determine the long-term oncological outcomes.
METHODS: Between 2016 and 2022, we prospectively followed all patients who underwent robotic resection for perihilar cholangiocarcinoma.
RESULTS: In total, 23 patients underwent robotic resection for perihilar cholangiocarcinoma, 18 receiving concomitant hepatectomy. The median age was 73 years. Operative time was 470 min with an estimated blood loss of 150 mL. No intraoperative conversions to open or other intraoperative complications occurred. Median length of stay was 5 days. Four postoperative complications occurred. Three readmissions occurred within 30 days with one 90-day mortality. R0 resection was achieved in 87% of patients and R1 in 13% of patients. At a median follow-up of 27 months, 15 patients were alive without evidence of disease, two patients with local recurrence at 1 year, and six were deceased.
CONCLUSIONS: Utilization of the robotic platform for perihilar cholangiocarcinoma is safe and feasible with excellent perioperative outcomes. Further studies are needed to determine the long-term oncological outcomes.
摘要：
目的：我们的目的是描述机器人切除肝门部胆管癌的结果，迄今为止西半球最大的单一机构系列。
方法：在2016年至2022年之间，我们前瞻性随访了所有接受机器人切除术的肝门部胆管癌患者。
结果：总计，23例肝门部胆管癌患者接受机器人切除术，18例同时接受肝切除术。中位年龄为73岁。手术时间为470分钟，估计失血量为150mL。术中无中转开腹或其他术中并发症发生。平均逗留时间为5天。术后发生4例并发症。在30天内发生了3次再入院，其中1例90天死亡。87%的患者实现了R0切除，13%的患者实现了R1切除。中位随访时间为27个月,15名患者没有疾病的证据，两名患者在1年内局部复发，六人死亡。
结论：使用机器人平台治疗肝门部胆管癌安全可行，围手术期效果良好。需要进一步的研究来确定长期的肿瘤学结果。
方法：在2016年至2022年之间，我们前瞻性随访了所有接受机器人切除术的肝门部胆管癌患者。
结果：总计，23例肝门部胆管癌患者接受机器人切除术，18例同时接受肝切除术。中位年龄为73岁。手术时间为470分钟，估计失血量为150mL。术中无中转开腹或其他术中并发症发生。平均逗留时间为5天。术后发生4例并发症。在30天内发生了3次再入院，其中1例90天死亡。87%的患者实现了R0切除，13%的患者实现了R1切除。中位随访时间为27个月,15名患者没有疾病的证据，两名患者在1年内局部复发，六人死亡。
结论：使用机器人平台治疗肝门部胆管癌安全可行，围手术期效果良好。需要进一步的研究来确定长期的肿瘤学结果。
